HomeCompareHMTV vs JNJ

HMTV vs JNJ: Dividend Comparison 2026

HMTV yields 27.97% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HMTV wins by $87.4K in total portfolio value
10 years
HMTV
HMTV
● Live price
27.97%
Share price
$7.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$117.7K
Annual income
$14,648.53
Full HMTV calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — HMTV vs JNJ

📍 HMTV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHMTVJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HMTV + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HMTV pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HMTV
Annual income on $10K today (after 15% tax)
$2,377.62/yr
After 10yr DRIP, annual income (after tax)
$12,451.25/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, HMTV beats the other by $8,465.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HMTV + JNJ for your $10,000?

HMTV: 50%JNJ: 50%
100% JNJ50/50100% HMTV
Portfolio after 10yr
$74.0K
Annual income
$9,668.97/yr
Blended yield
13.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

HMTV
Analyst Ratings
4
Buy
Consensus: Buy
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HMTV buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHMTVJNJ
Forward yield27.97%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$117.7K$30.3K
Annual income after 10y$14,648.53$4,689.40
Total dividends collected$78.1K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: HMTV vs JNJ ($10,000, DRIP)

YearHMTV PortfolioHMTV Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$13,497$2,797.20$10,592$272.30+$2.9KHMTV
2$17,970$3,528.45$11,289$357.73+$6.7KHMTV
3$23,619$4,390.52$12,123$472.89+$11.5KHMTV
4$30,665$5,393.02$13,141$629.86+$17.5KHMTV
5$39,356$6,543.88$14,408$846.81+$24.9KHMTV
6$49,960$7,848.97$16,021$1,151.60+$33.9KHMTV
7$62,769$9,311.94$18,122$1,588.22+$44.6KHMTV
8$78,097$10,934.04$20,930$2,228.20+$57.2KHMTV
9$96,277$12,714.09$24,792$3,191.91+$71.5KHMTV
10$117,665$14,648.53$30,274$4,689.40+$87.4KHMTV

HMTV vs JNJ: Complete Analysis 2026

HMTVStock

Hemisphere Media Group, Inc. operates as the Spanish-language media company. The company operates Pantaya, a subscription streaming service of Spanish-language media with approximately million subscribers; Cinelatino, a cable movie network with approximately 17.1 million subscribers in the United States, Latin America, and Canada; WAPA, a broadcast television network and television content producer; WAPA.TV, a news and entertainment website, as well as mobile apps, featuring content produced by WAPA; and WAPA Deportes, a sports television network in Puerto Rico. It also operates WAPA America, a cable television network that serves approximately 3.3 million subscribers in the United States; and Pasiones, a cable television network, which showcases telenovelas and serialized dramas to approximately 3.7 million subscribers in the United States and 15.4 million subscribers in Latin America. In addition, the company operates Centroamerica TV, a cable television network that provides news and entertainment, and soccer programming to approximately 3.2 million subscribers in the United States; and Television Dominicana, a cable television network, which offers news and entertainment programs to approximately 2.2 million subscribers in the United States. Further, it operates Snap Media, a distributor of content to broadcast and cable television networks; and over-the-top, and subscription and advertising video-on-demand platforms in Latin America; and REMEZCLA: a digital media company targeting English-speaking and the bilingual U.S. Hispanic millennials. The company was incorporated in 2013 and is headquartered in Coral Gables, Florida. As of September 13, 2022, Hemisphere Media Group, Inc. was taken private.

Full HMTV Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this HMTV vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HMTV vs SCHDHMTV vs JEPIHMTV vs OHMTV vs KOHMTV vs MAINHMTV vs ABBVHMTV vs MRKHMTV vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.